Common variance! [Design Issues]

posted by jag009  – NJ, 2012-06-11 19:25 (5120 d 02:49 ago) – Posting: # 8685
Views: 11,241

Hi Helmut,

❝ Right. But there’s another problem: In this type of higher-order XOver you obtain a common (pooled) variance from treatment variances. What if one of the formulations not only shows a PE far away from 100% (which would lead to dropping it from development), but performs ‘bad’ in terms of the CV? Especially if MR formulations are concerned, the differences sometimes are large. This formulation will inflate your CIs and require a larger sample size compared to simple XOvers. We had a similar debate in the EU where EMA in their drafted GL wanted to see a four-way XOver T and R (fed/fasting). In the final GL such a design is not required.


Agreed. I forgot to say that a larger sample size will also serve to compensate for the widening of the CIs due to potential increase in variations due to formulation performance differences. Now how much of an increase in sample size is the problem... Like you said we don't know how bad 1 or 2 out of the 3 test formulations will perform.

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
177 visitors (0 registered, 177 guests [including 14 identified bots]).
Forum time: 22:15 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5